rs1053049 — PPARD 3'UTR variant

3'UTR variant in PPARD that acts as the third tag in the elite athlete haplotype (rs2267668/rs2016520/rs1053049); TC carriers show enhanced skeletal muscle glucose uptake and insulin sensitivity; the A/C/C haplotype containing this C allele is dramatically underrepresented in elite athletes

See your personal result for PPARD

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

PPARD 3'UTR Variant — The Third Piece of the Elite Athlete Haplotype

PPARδ11 PPARδ
Peroxisome Proliferator-Activated Receptor delta — a nuclear receptor that coordinates gene expression programs for fatty acid oxidation, mitochondrial biogenesis, and muscle fiber-type switching in skeletal muscle is encoded by the PPARD gene on chromosome 6. The rs1053049 variant sits in the 3' untranslated region (3'UTR) of exon 9 — a regulatory stretch of RNA that is not translated into protein but profoundly influences how much PPARD mRNA is produced, how long it persists in the cell, and ultimately how much PPARδ protein is available to drive its downstream program.

This SNP is the third of three tag variants in the PPARD gene that together define a haplotype with striking consequences for elite athletic potential. Alongside rs2267668 (5' region) and rs2016520 (5'UTR, +294T>C), rs1053049 completes the A/C/C haplotype that has been studied in competitive athletes across multiple cohorts. It was identified as an independently significant marker for elite athletic status in its own right, with additional effects on skeletal muscle insulin sensitivity and body composition response to exercise.

The Mechanism

The 3'UTR is a post-transcriptional control hub. Variants in this region can disrupt or create microRNA binding sites22 microRNA binding sites
MicroRNAs are short non-coding RNAs that bind to complementary sequences in the 3'UTR of target mRNAs, triggering degradation or translational repression. A single 3'UTR SNP can abolish or create such a binding site, altering the amount of protein produced from an unchanged coding sequence, alter mRNA secondary structure affecting transcript stability, or modify polyadenylation signals that control mRNA half-life. While the precise molecular mechanism for rs1053049 has not been elucidated by in vitro reporter assays at the same level of detail as the rs2016520 promoter variant, the pattern of phenotypic associations — particularly the contrast between TT and TC genotypes for skeletal muscle glucose uptake — is consistent with a functional effect on PPARD expression levels in muscle tissue.

The key distinction from rs2016520 is anatomical: the 5'UTR variant (rs2016520) primarily affects transcriptional initiation through Sp-1 binding, while a 3'UTR variant like rs1053049 is more likely to influence post-transcriptional stability or translation efficiency. These mechanisms can have tissue-specific effects, which helps explain why the two variants show partially overlapping but distinct associations across metabolic, athletic, and body composition phenotypes.

The Evidence

The foundational study on rs1053049's metabolic significance was conducted by Vänttinen et al. at the University of Turku33 Vänttinen et al. at the University of Turku
Vänttinen M et al. Single nucleotide polymorphisms in the peroxisome proliferator–activated receptor δ gene are associated with skeletal muscle glucose uptake. Diabetes, 2005. In 129 healthy subjects who underwent euglycemic hyperinsulinemic clamp procedures with PET imaging, the TC genotype of rs1053049 was significantly associated with higher whole-body and skeletal muscle glucose uptake compared with TT homozygotes (P = 0.028). This was a direct measurement of in vivo insulin sensitivity at the tissue level, not an association with a proxy marker, and it established that rs1053049 independently modulates how efficiently skeletal muscle takes up glucose in response to insulin.

A lifestyle intervention study using whole-body MRI44 lifestyle intervention study using whole-body MRI
Thamer C et al. Variations in PPARD determine the change in body composition during lifestyle intervention: a whole-body magnetic resonance study. J Clin Endocrinol Metab, 2008 found that PPARD rs1053049 (along with rs6902123 and rs2267668) significantly affected the magnitude of lifestyle-intervention-induced changes in adiposity, hepatic fat storage, and relative muscle mass. Carriers of the minor C allele showed less reduction in adipose tissue mass (both nonvisceral and visceral, P = 0.02 and P = 0.01 respectively) and hepatic lipids (P = 0.04) in response to a structured diet and exercise program. This finding provides a mechanistic basis for why PPARD variation contributes to individual differences in body composition response to training and identifies rs1053049 as a predictor of whether lifestyle intervention will yield the expected adipose tissue reduction.

The landmark haplotype analysis of 660 elite athletes55 haplotype analysis of 660 elite athletes
Maciejewska-Karlowska A et al. Genomic haplotype within the Peroxisome Proliferator-Activated Receptor Delta (PPARD) gene is associated with elite athletic status. Scand J Med Sci Sports, 2014 demonstrated that rs1053049 was individually associated with overall elite athletic performance (P = 0.0002) and specifically with strength-endurance sport athletes (P = 0.0003) when comparing 660 elite Polish athletes to 704 healthy controls. Crucially, the haplotype analysis showed that the complete A/C/C haplotype across all three PPARD variants (rs2267668-A / rs2016520-C / rs1053049-C) was dramatically underrepresented in every subgroup of elite athletes compared with controls (P < 0.000001). This is one of the strongest haplotype associations ever reported in sports genomics, and it establishes that the C allele at rs1053049 — in haplotype context with the other two variants — is associated with lower elite athletic potential.

A 12-week training intervention in 168 Polish women66 12-week training intervention in 168 Polish women
Leońska-Duniec A et al. The polymorphisms of the PPARD gene modify post-training body mass and biochemical parameter changes in women. PLOS One, 2018 found that TT homozygotes at rs1053049 were overrepresented in the group with higher post-training triglyceride levels. Haplotype analysis revealed that the G/C/C haplotype (rs2267668-G / rs2016520-C / rs1053049-C) was associated with post-training increases in fat-free mass and lower levels of cholesterol and triglycerides — suggesting that the broader haplotype context around rs1053049 determines whether the C allele is favorable or unfavorable for a given metabolic phenotype.

A 2023 Chinese military exerciser study77 2023 Chinese military exerciser study
Correlation between PPARD rs2267668 and rs1053049 polymorphisms with lower-limb strength in Chinese male exercisers. Mil Med Sci, 2023 found that the TT genotype of rs1053049 was significantly more common in the strong lower-limb strength group than in the weak group (64.7% vs 44.6%, P = 0.011), and the T allele frequency was higher in stronger exercisers (81.6% vs 66.2%, P = 0.004), supporting the idea that the T allele at this 3'UTR site confers an advantage for lower-body power output in trained individuals.

Practical Actions

The metabolic picture at rs1053049 is nuanced. TT homozygotes show higher skeletal muscle glucose uptake efficiency in response to strength training and may have an advantage for lower-limb power development. However, TT carriers also tend to show higher post-training triglyceride levels in some aerobic training contexts, suggesting that dietary fat quality and omega-3 supplementation are particularly relevant for TT individuals.

TC carriers show the highest measured insulin sensitivity in skeletal muscle (Vänttinen 2005 euglycemic clamp data) and may represent an intermediate metabolic phenotype. CC homozygotes appear to have reduced response to lifestyle-intervention-induced fat loss and are part of the haplotype most underrepresented in elite athletes, suggesting that the double-C genotype confers less favorable body composition adaptations to training.

Regardless of genotype, omega-3 fatty acids (EPA and DHA) are natural PPARδ ligands that directly activate the receptor protein — nutritionally amplifying the same fat-oxidation and metabolic programs that this variant affects at the gene expression level.

Interactions

rs1053049 is one of three PPARD haplotype tag SNPs; the others are rs2267668 (5' region) and rs2016520 (5'UTR +294T>C, already profiled separately). The full haplotype (rs2267668/rs2016520/rs1053049) is more predictive of elite athletic potential than any individual SNP, with the A/C/C haplotype showing p < 0.000001 for underrepresentation in elite athletes. Understanding your genotype at all three sites provides the most complete picture of your PPARD haplotype and its implications.

PPARGC1A rs8192678 (Gly482Ser), encoding PGC-1alpha — the transcriptional coactivator that physically partners with PPARδ to drive mitochondrial biogenesis — interacts powerfully with the PPARD locus as a whole. PPARD CC at rs2016520 combined with PPARGC1A Gly/Gly yields OR 8.32 for elite endurance status; the rs1053049 genotype adds further context to where an individual falls within this receptor-coactivator interaction.

Nutrient Interactions

fatty acids altered_metabolism
glucose altered_metabolism

Genotype Interpretations

What each possible genotype means for this variant.

TT Major Allele Normal

Common PPARD 3'UTR genotype — typical fat-oxidation baseline with strong training responsiveness

The T allele at the rs1053049 3'UTR site is associated with normal-to-favorable PPARD expression in skeletal muscle. Research using euglycemic clamp + PET imaging found that TT carriers have baseline (rather than elevated) skeletal muscle glucose uptake compared to TC carriers, which means that insulin sensitivity at this locus is not the TT genotype's primary advantage.

Where TT shines is in training responsiveness and strength development. A systematic review by Petr et al. identified PPARD rs1053049 TT as one of the best aerobic training-responder genotypes. A 2023 study of Chinese male exercisers (n = 133) found TT frequency was 64.7% in the strong lower-limb strength group vs 44.6% in the weak group (P = 0.011). This suggests the T allele is associated with more favorable neuromuscular and power adaptations to training.

In the context of the PPARD haplotype, TT at rs1053049 breaks the unfavorable A/C/C haplotype — individuals who carry TT here are not part of the haplotype most underrepresented in elite athletes, which is reassuring in terms of athletic potential.

CT Heterozygote Normal

One copy of the 3'UTR C allele — enhanced skeletal muscle insulin sensitivity

The association between TC genotype and enhanced skeletal muscle glucose uptake (Vänttinen et al. 2005, Diabetes) is noteworthy because it was measured directly in tissue using PET imaging during a euglycemic hyperinsulinemic clamp — not inferred from fasting glucose or surrogate markers. This means the TC genotype's advantage in insulin sensitivity is a reproducible in vivo finding at the organ level.

In the haplotype context, carrying one C allele at rs1053049 means you may carry the C allele as part of the broader PPARD haplotype block. Whether this C allele is embedded in the unfavorable haplotype depends on the surrounding PPARD variants. Viewed individually, the TC genotype represents an intermediate phenotype between the TT (high lower-limb strength, normal glucose uptake) and CC (reduced training-induced fat loss) ends of the spectrum.

For body composition response, TC carriers occupy a middle ground: they tend to show better adipose tissue reduction with lifestyle intervention than CC homozygotes, and the G/C/C haplotype (which contains this C allele) was associated with favorable lipid changes after training in some studies.

CC Minor Allele Homozygote Reduced

Two copies of the 3'UTR C allele — reduced body composition response to lifestyle intervention

The body composition finding from Thamer et al. 2008 is particularly relevant for CC carriers: in subjects undergoing a structured diet-and-exercise lifestyle intervention, carriers of the minor C allele showed significantly attenuated reductions in both nonvisceral adipose tissue (P = 0.02), visceral adipose tissue (P = 0.01), and hepatic lipids (P = 0.04) compared with TT homozygotes — measured directly by whole-body magnetic resonance imaging. As a CC homozygote, you carry two copies of the attenuating allele, placing you at the furthest end of the reduced- response spectrum for fat loss with lifestyle intervention.

In the haplotype analysis by Maciejewska-Karlowska et al. (2014), the complete A/C/C haplotype (with this CC genotype as the rs1053049 component) was underrepresented at p < 0.000001 in 660 elite athletes across all four sport categories. The effect was consistent across endurance athletes, strength-endurance athletes, speed-strength athletes, and games athletes alike — a breadth of association unusual in sports genomics.

The mechanistic basis is not fully characterized, but 3'UTR variants can affect mRNA stability through microRNA binding sites and secondary structure changes. The downstream consequence — reduced adaptability of body composition and fat metabolism to exercise stimuli — suggests a regulatory effect on PPARD expression or translational efficiency in muscle and adipose tissue.

Note: the skeletal muscle glucose uptake advantage observed in TC carriers does not appear to translate proportionally to CC homozygotes based on available data.